Biomarin Pharmaceutical Inc (BMRN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $64.65 (-0.66%), Market cap $10.01B, P/E ratio 37.27, 52-week low–high $49.67 ~ $64.08.
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe)
Financial statements, price targets, institutional (13F) holdings and related news for Biomarin Pharmaceutical Inc are updated in real time on BlackAll Trade.
Biomarin Pharmaceutical Inc trades at $64.65 (-0.66%). Real-time quotes and charts are available on BlackAll Trade.
Biomarin Pharmaceutical Inc has a market cap of about $10.01B. Its P/E ratio is 37.27.
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Eur